Korro Bio (KRRO) Current Deferred Revenue (2019 - 2026)
Korro Bio's (KRRO) quarterly Current Deferred Revenue came in at $179000.0 in Q1 2026, down 93.61% YoY from $2.8 million in Q1 2025, and down 94.63% on a QoQ basis from $3.3 million in Q3 2025.
Korro Bio (KRRO) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has 6 years of Current Deferred Revenue data on file, last reported at $179000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 93.61% year-over-year to $179000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179000.0 (down 93.61% YoY) and the FY2024 annual result came in at $3.5 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $179000.0 in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.9 million in Q2 2025 to a low of $179000.0 in Q1 2026.
- A 3-year average of $2.7 million and a median of $3.1 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue jumped 51.39% — and 2026, when it slumped 93.61%.
- Tracing KRRO's Current Deferred Revenue over 3 years: stood at $3.5 million in 2024, then dropped by 5.15% to $3.3 million in 2025, then slumped by 94.63% to $179000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $179000.0 (Q1 2026), $3.3 million (Q3 2025), and $3.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Mn |
| Mar 31, 2026 | 179,000.00 |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.93 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Mar 31, 2021 | 9.42 Mn |
| Dec 31, 2020 | 14.07 Mn |
| Sep 30, 2020 | 24.02 Mn |
| Jun 30, 2020 | 35.27 Mn |
| Mar 31, 2020 | 38.67 Mn |
| Dec 31, 2019 | 48.15 Mn |
| Sep 30, 2019 | 49.36 Mn |